QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
Log in
NASDAQ:CHMA

Chiasma Stock Forecast, Price & News

$3.95
+0.06 (+1.54 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.88
Now: $3.95
$4.00
50-Day Range
$3.85
MA: $4.13
$4.89
52-Week Range
$2.88
Now: $3.95
$7.75
Volume801,805 shs
Average Volume1.44 million shs
Market Capitalization$228.33 million
P/E RatioN/A
Dividend YieldN/A
Beta1.59
Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.
Chiasma logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CHMA
CUSIPN/A
Phone617-928-5300
Employees85
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.04 per share

Profitability

Net Income$-36,320,000.00

Miscellaneous

Market Cap$228.33 million
Next Earnings Date3/4/2021 (Confirmed)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.66 out of 5 stars

Medical Sector

272nd out of 1,966 stocks

Pharmaceutical Preparations Industry

130th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$3.95
+0.06 (+1.54 %)
(As of 03/1/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CHMA News and Ratings via Email

Sign-up to receive the latest news and ratings for CHMA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Chiasma (NASDAQ:CHMA) Frequently Asked Questions

Is Chiasma a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Chiasma stock.
View analyst ratings for Chiasma
or view top-rated stocks.

What stocks does MarketBeat like better than Chiasma?

Wall Street analysts have given Chiasma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Chiasma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Chiasma?

Chiasma saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 2,490,000 shares, a decrease of 15.6% from the December 31st total of 2,950,000 shares. Based on an average trading volume of 1,030,000 shares, the short-interest ratio is presently 2.4 days.
View Chiasma's Short Interest
.

When is Chiasma's next earnings date?

Chiasma is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for Chiasma
.

How can I listen to Chiasma's earnings call?

Chiasma will be holding an earnings conference call on Thursday, March 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Chiasma's earnings last quarter?

Chiasma, Inc. (NASDAQ:CHMA) issued its earnings results on Thursday, November, 5th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.41) by $0.11. The biotechnology company had revenue of $0.14 million for the quarter.
View Chiasma's earnings history
.

How has Chiasma's stock been impacted by Coronavirus (COVID-19)?

Chiasma's stock was trading at $3.92 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CHMA shares have increased by 0.8% and is now trading at $3.95.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CHMA?

3 analysts have issued twelve-month price targets for Chiasma's shares. Their forecasts range from $8.00 to $15.00. On average, they expect Chiasma's share price to reach $11.00 in the next year. This suggests a possible upside of 178.5% from the stock's current price.
View analysts' price targets for Chiasma
or view top-rated stocks among Wall Street analysts.

Who are Chiasma's key executives?

Chiasma's management team includes the following people:
  • Mr. Raj Kannan, Pres, CEO & Director (Age 56, Pay $475.78k)
  • Mr. Lee Giguere, VP & Gen. Counsel (Age 41, Pay $134.52k)
  • Mr. Mark J. Fitzpatrick, Consultant (Age 58, Pay $788.3k)
  • Dr. William H. Ludlam, Sr. VP of Clinical Devel. & Medical Affairs (Age 56, Pay $520.92k)
  • Mr. John Brendan Doyle, CFO & Treasurer (Age 43)
  • Mr. Drew Enamait, VP of Fin. & Admin. (Age 47)
  • Ms. Dawn Schottlandt CFA, VP of Investor Relations & Corp. Communications
  • Mr. Anand Varadan, Exec. VP & Chief Commercial Officer (Age 54)
  • Mr. Derek Brown, VP of Marketing
  • Mr. Joe Lyons, Exec. Director of HR

Who are some of Chiasma's key competitors?

What other stocks do shareholders of Chiasma own?

When did Chiasma IPO?

(CHMA) raised $76 million in an initial public offering (IPO) on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

What is Chiasma's stock symbol?

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

Who are Chiasma's major shareholders?

Chiasma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.34%), Bruce & Co. Inc. (1.82%), The Manufacturers Life Insurance Company (1.38%), Ikarian Capital LLC (1.26%), Stonepine Capital Management LLC (1.25%) and Renaissance Technologies LLC (1.11%). Company insiders that own Chiasma stock include David M Stack, Raj Kannan, Roni Mamluk, Scott Minick and William Ludlam.
View institutional ownership trends for Chiasma
.

Which institutional investors are selling Chiasma stock?

CHMA stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Nuveen Asset Management LLC, Barclays PLC, and GSA Capital Partners LLP.
View insider buying and selling activity for Chiasma
or view top insider-selling stocks.

Which institutional investors are buying Chiasma stock?

CHMA stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Bruce & Co. Inc., BlackRock Inc., Healthcare of Ontario Pension Plan Trust Fund, Healthcare of Ontario Pension Plan Trust Fund, Stonepine Capital Management LLC, The Manufacturers Life Insurance Company , and State of Wisconsin Investment Board. Company insiders that have bought Chiasma stock in the last two years include David M Stack, Raj Kannan, Scott Minick, and William Ludlam.
View insider buying and selling activity for Chiasma
or or view top insider-buying stocks.

How do I buy shares of Chiasma?

Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chiasma's stock price today?

One share of CHMA stock can currently be purchased for approximately $3.95.

How much money does Chiasma make?

Chiasma has a market capitalization of $228.33 million. The biotechnology company earns $-36,320,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis.

How many employees does Chiasma have?

Chiasma employs 85 workers across the globe.

What is Chiasma's official website?

The official website for Chiasma is www.chiasmapharma.com.

Where are Chiasma's headquarters?

Chiasma is headquartered at 140 Kendrick Street Building C East, Needham MA, 02494.

How can I contact Chiasma?

Chiasma's mailing address is 140 Kendrick Street Building C East, Needham MA, 02494. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.